An interventional study of Forward to Quit (F2Q) in Smoking Cessation, sponsored by University of Colorado, Denver. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-30.
Sponsored by University of Colorado, Denver · Not applicable, Interventional, and Treatment
This study evaluates the feasibility, acceptability, and preliminary efficacy of "Forward to Quit" (F2Q), a person-centered mobile health (mHealth) smoking cessation intervention designed specifically for transgender adults. The intervention was developed in collaboration with transgender individuals and gender-affirming healthcare providers. The study includes usability testing and a remote single-arm pilot trial. Primary outcomes include feasibility and acceptability of both the intervention and remote biochemical verification of smoking cessation. Secondary outcomes include self-reported and biochemically verified smoking cessation, as well as changes in psychosocial factors such as social support and gender affirmation. The goal is to inform a future large-scale trial and address tobacco-related health disparities in transgender populations.
304 studies on the registry are indexed under Smoking Cessation; 139 are open to participants now.
This study's enrollment of 47 is below the median of 154 across 285 interventional studies indexed under Smoking Cessation.
Browse Smoking Cessation studies →University of Colorado, Denver is the lead sponsor of 1,499 studies on the registry; 315 are open to participants now.
Of its 139 completed or terminated interventional studies of FDA-regulated products, 89 (64%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Participants will receive access to the Forward to Quit (F2Q) mHealth smoking cessation intervention tailored for transgender adults
Behavioral: Forward to Quit (F2Q)
A mobile health (mHealth) smoking cessation intervention designed specifically for transgender adults. Delivered via a secure website accessible by smartphone or tablet.
Intervention Acceptability
We will assess participants' perceptions of information quality and usefulness as well as overall satisfaction with the intervention. If the average score across all items is \>=6 on a 7-point scale for 90% of participants after using intervention for 3 months, we will consider intervention to be acceptable.
Time frame: 3 months post-baseline
Intervention feasibility
Feasibility will be met if retention rates are at least 80%.
Time frame: 3 months post-baseline
Remote biochemical data collection acceptability
We will measure participants' perceived difficulty, satisfaction, and comfort with remote biochemical verification. If scores are \>=6 on a 7-point scale for 90% of participants, we will consider remote biochemical verification to be acceptable.
Time frame: 3 month post-baseline
Remote biochemical data collection feasibility
Completion rate (percentage of eligible participants who submit biochemical samples for verification of tobacco abstinence)
Time frame: 3 months post-baseline
Smoking cessation
Participants will be categorized as abstinent or not abstinent based on self-report.
Time frame: 3 month post-baseline
Conceptual model covariates
Nicotine dependence and other conceptual model covariates will be assessed with validated survey items.
Time frame: 3 months post-baseline
Plan to share: Undecided — Unsure of where or how IPD would be shared
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Colorado, Denver